Your Blood Sugar Is Fine. Your Metabolic Shock Absorbers Are Not

Two European geriatricians argue that insulin resistance in older people has been badly misfiled. In the young and obese it is a disease of excess fat. In the old it is something else: a readout of how much spare capacity the body has left across muscle, fat tissue, and brain. The paper assembles existing evidence that ageing muscle loses metabolic competence before it loses bulk, that ageing fat tissue turns into an inflammatory organ regardless of how much of it there is, and that the brain becomes insulin resistant in ways that track with memory loss and late-life depression. The authors conclude that chasing blood glucose in older patients treats the dashboard light rather than the engine, and propose measuring muscle strength, body composition and physical performance alongside metabolic markers. The argument is coherent and clinically sensible.

The standard story about insulin resistance goes like this: you eat too much, you store too much fat, your cells stop listening to insulin, and eventually you get type 2 diabetes. It is a good story for a 45-year-old with a large waist. Boccardi and Sinclair argue it is close to useless for a 70-year-old.

Their evidence is the mismatch. In older populations insulin resistance shows up routinely in people who are not obese, appears years or decades before any diabetes diagnosis, and arrives in company that has nothing to do with glucose: weakness, slow walking, falls, memory complaints, low mood. Two people of the same age and the same body mass index can sit at opposite ends of the insulin sensitivity range.

The paper’s answer is physiological reserve, a formal way of saying spare capacity. Skeletal muscle is the body’s largest glucose sink, absorbing most of what you eat after a meal. Ageing muscle does not simply shrink. It changes character first: fast-twitch fibres are lost preferentially, fat infiltrates between and inside the fibres, mitochondria become less efficient, and the tissue stops responding to protein the way it used to. Clamp studies find older adults with normal muscle bulk still handling glucose poorly. The buffer degrades before the volume does.

Fat tissue undergoes a parallel conversion. It migrates inward toward the viscera even in people whose weight never changes, fills with inflammatory immune cells, and accumulates senescent cells that leak inflammatory signals into the circulation. Once fat loses its capacity to store lipid safely, the overflow lands in liver and muscle, where it directly interferes with insulin signalling.

Then the brain. Insulin crosses into the brain less readily with age and neuronal insulin signalling degrades, which the authors link to reduced cerebral glucose uptake, impaired synaptic function, and the well-documented associations between insulin resistance, cognitive decline and late-life depression.

The practical consequence is the interesting part. If insulin resistance in older adults is a symptom of eroding reserve rather than a disease of sugar, then a drug that normalises glucose while stripping muscle mass has made the underlying problem worse. The authors are pointed about GLP-1 agonists and SGLT2 inhibitors in frail patients for exactly this reason. Their proposed alternative is to judge treatments by whether they preserve muscle function, dampen inflammation and protect cognition, with glucose control retained as one component rather than the target.

Actionable Insights

Take-home messages with real magnitudes. Cohen’s d below measures how far a treated group shifts relative to an untreated one. Roughly: 0.2 is small, 0.5 moderate, 0.8 large.

Lift weights. In adults over 60, resistance training improved insulin resistance with d of -0.25 (95% CI -0.43 to -0.06) and HbA1c with d of -0.51 (95% CI -0.84 to -0.18), pooled across 12 trials. In plain terms, the average trainee ends up better than about 60% of non-trainees on insulin resistance and about 70% on blood sugar control. Real, modest, and requiring no weight loss.

Intensive lifestyle change is the strongest effect on this list. In the Diabetes Prevention Program, diabetes incidence fell from 11.0 to 4.8 cases per 100 person-years, a 58% reduction (95% CI 48 to 66). About seven people needed treating for three years to prevent one case.

Structured exercise plus nutrition in frail older diabetics improved physical performance by 0.85 points on a 12-point scale (95% CI 0.44 to 1.26), roughly d of 0.4. Note what it did not do: no reduction in death, hospitalisation, or improvement in quality of life.

Distribute protein across meals rather than loading dinner.

Context and Source

  • Open Access Paper: Rethinking insulin resistance in aging: A reserve-oriented clinical framework
  • Authors: Virginia Boccardi (corresponding), Alan J. Sinclair
  • Institutions: Division of Gerontology and Geriatrics, Department of Medicine and Surgery, University of Perugia, Italy; Foundation for Diabetes Research in Older People (fDROP) and King’s College London, UK
  • Countries: Italy and United Kingdom
  • Journal: Ageing Research Reviews (Elsevier), Volume 119, article 103180, 2026
  • Article type: Review Article, narrative. online 17 May 2026.
  • Impact evaluation: The impact score of this journal is 15.5, evaluated against a typical high-end range of 0 to 60 plus for top general science, therefore this is a High impact journal.
1 Like

Follow up Prompt:

Is this “standard story” useful for a 60 year old person also, or is the 60 year old more like the 70 year old mentioned in the text summary above?

Claude Response:

Short answer: 60 is closer to the 45-year-old case than the 70-year-old case for most people, and the evidence on that is stronger than you might expect. But age is the wrong variable to be indexing on, and there is a specific behavioral transition that does happen around 60.

The paper never names an age. Boccardi and Sinclair say “older adults” throughout and never define it. The geriatric trials they lean on mostly enrolled 70+, and MID-FRAIL required age 70 or over. So the framework was built on evidence from people substantially older than 60.

The standard story does not just still work at 60, it works better. In the Diabetes Prevention Program, the lifestyle arm cut diabetes incidence by 58% overall but by 71% in participants aged 60 and older, the largest effect of any subgroup. At ten-year follow-up the older lifestyle group still showed a 49% delay. Eat less, move more, lose visceral fat is not a story that expires at 60. It is the age band where it delivered its biggest measured payoff.

The interesting asymmetry is the drug half. Metformin in the DPP worked best in people aged 25 to 44 and was not effective in the 60-plus group. So what fades with age is the pharmacological shortcut, not the lifestyle mechanism.

There is also a direct empirical challenge to the paper’s core thesis. A JCI review of metabolic changes in ageing concludes that after you account for adiposity and fat distribution, age and fitness do not predict insulin action with respect to glucose metabolism. If that holds, then insulin resistance in a 60-year-old is still mostly a fat-distribution problem wearing an age costume, and the “ageing per se” framing Boccardi and Sinclair build on is overstated. I would treat this as a genuine open dispute rather than settled either way.

What actually flips the switch is phenotype, not birthday. The numbers that matter at 60: muscle is being lost at roughly 0.7 to 0.8% per year, a 60-year-old man has about 14% less leg muscle than a 20-year-old, body fat has been climbing about 1% per year since the 40s, and strength is declining 2.5 to 4% per year, three to five times faster than mass. That last figure is the whole point of the paper compressed into one statistic. Quality degrades faster than quantity.

So the discriminating question is not how old you are. It is: is your waist expanding while your weight stays flat, and is your grip strength or chair-stand time getting worse? A 60-year-old with a large waist and preserved strength is squarely in the standard story, and should treat it as a fat problem. A 60-year-old with a normal BMI, a creeping waistline, and slipping function is already in the reserve regime and would be misled by a normal weight and a normal HbA1c.

The one thing that genuinely does change around 60 is the risk calculus on weight loss itself. At 45, losing weight is close to pure upside. At 70, losing weight without concurrent resistance training and adequate protein measurably accelerates sarcopenia. Sixty is roughly where you should stop losing weight indiscriminately and start only losing weight while lifting. That is the real transition, and it is a change in how you execute, not a change in whether the standard story applies.

Worth saying plainly: this is analysis of published evidence, not individualized medical advice, and the phenotype question above is one a clinician can answer for a specific person with a tape measure, a grip dynamometer, and a DEXA scan in about twenty minutes.